Intellia Therapeutics Price to Book Ratio 2015-2021 | NTLA

Historical price to book ratio values for Intellia Therapeutics (NTLA) over the last 10 years. The current price to book ratio for Intellia Therapeutics as of October 15, 2021 is 19.38.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Intellia Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-15 130.49 18.02
2021-06-30 161.91 $7.24 22.36
2021-03-31 80.26 $8.04 9.98
2020-12-31 54.40 $7.96 6.84
2020-09-30 19.88 $5.61 3.55
2020-06-30 21.02 $5.99 3.51
2020-03-31 12.23 $4.90 2.50
2019-12-31 14.67 $5.38 2.73
2019-09-30 13.35 $5.64 2.37
2019-06-30 16.37 $5.80 2.82
2019-03-31 17.08 $5.81 2.94
2018-12-31 13.65 $6.15 2.22
2018-09-30 28.62 $6.07 4.71
2018-06-30 27.36 $6.47 4.23
2018-03-31 21.09 $6.86 3.08
2017-12-31 19.22 $7.09 2.71
2017-09-30 24.85 $4.87 5.10
2017-06-30 16.00 $5.20 3.08
2017-03-31 14.09 $5.55 2.54
2016-12-31 13.11 $5.83 2.25
2016-09-30 17.02 $6.06 2.81
2016-06-30 21.35 $6.21 3.44
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.589B $0.058B
Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00